China Resources Double-Crane Pharmaceutical Co Ltd
China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People's Republic of China. The company offers pharmaceutical products for blood pressure, blood sugar, injection, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 an… Read more
China Resources Double-Crane Pharmaceutical Co Ltd (600062) - Total Liabilities
Latest total liabilities as of September 2025: CN¥4.85 Billion CNY
Based on the latest financial reports, China Resources Double-Crane Pharmaceutical Co Ltd (600062) has total liabilities worth CN¥4.85 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
China Resources Double-Crane Pharmaceutical Co Ltd - Total Liabilities Trend (1994–2024)
This chart illustrates how China Resources Double-Crane Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
China Resources Double-Crane Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of China Resources Double-Crane Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
YUNDA Holding Co Ltd
SHE:002120
|
China | CN¥15.66 Billion |
|
Graham Holdings Co
NYSE:GHC
|
USA | $3.31 Billion |
|
Haemonetics Corporation
NYSE:HAE
|
USA | $1.58 Billion |
|
Penske Automotive Group Inc
NYSE:PAG
|
USA | $12.02 Billion |
|
McGrath RentCorp
NASDAQ:MGRC
|
USA | $1.12 Billion |
|
Waaree Energies Limited
NSE:WAAREEENER
|
India | ₹129.22 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥6.46 Billion |
|
Drax Group plc
PINK:DRXGF
|
USA | $2.78 Billion |
Liability Composition Analysis (1994–2024)
This chart breaks down China Resources Double-Crane Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how China Resources Double-Crane Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for China Resources Double-Crane Pharmaceutical Co Ltd (1994–2024)
The table below shows the annual total liabilities of China Resources Double-Crane Pharmaceutical Co Ltd from 1994 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥5.57 Billion | +53.09% |
| 2023-12-31 | CN¥3.64 Billion | -2.98% |
| 2022-12-31 | CN¥3.75 Billion | +17.30% |
| 2021-12-31 | CN¥3.20 Billion | +5.26% |
| 2020-12-31 | CN¥3.04 Billion | +16.89% |
| 2019-12-31 | CN¥2.60 Billion | +8.46% |
| 2018-12-31 | CN¥2.40 Billion | +50.85% |
| 2017-12-31 | CN¥1.59 Billion | +32.11% |
| 2016-12-31 | CN¥1.20 Billion | -9.49% |
| 2015-12-31 | CN¥1.33 Billion | +42.17% |
| 2014-12-31 | CN¥934.93 Million | -18.32% |
| 2013-12-31 | CN¥1.14 Billion | -36.44% |
| 2012-12-31 | CN¥1.80 Billion | +3.89% |
| 2011-12-31 | CN¥1.73 Billion | +35.49% |
| 2010-12-31 | CN¥1.28 Billion | +8.24% |
| 2009-12-31 | CN¥1.18 Billion | +5.69% |
| 2008-12-31 | CN¥1.12 Billion | -14.53% |
| 2007-12-31 | CN¥1.31 Billion | +3.53% |
| 2006-12-31 | CN¥1.26 Billion | -32.55% |
| 2005-12-31 | CN¥1.87 Billion | -18.45% |
| 2004-12-31 | CN¥2.30 Billion | -9.57% |
| 2003-12-31 | CN¥2.54 Billion | +26.33% |
| 2002-12-31 | CN¥2.01 Billion | +60.12% |
| 2001-12-31 | CN¥1.26 Billion | +99.76% |
| 2000-12-31 | CN¥628.89 Million | +32.79% |
| 1999-12-31 | CN¥473.60 Million | +137.31% |
| 1998-12-31 | CN¥199.57 Million | +96.08% |
| 1997-12-31 | CN¥101.78 Million | +109.89% |
| 1996-12-31 | CN¥48.49 Million | +66.25% |
| 1995-12-31 | CN¥29.17 Million | -19.92% |
| 1994-12-31 | CN¥36.42 Million | -- |